UCSF researchers have developed a platform capable of producing mAbs that target post-translational modifications such as phosphorylation. The technology could open up a host of new targets for cancer and other diseases associated with aberrant modifications. Next, the team will have to show that the mAbs target endogenous proteins in vivo.